147
Views
5
CrossRef citations to date
0
Altmetric
Review

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy

, &
Pages 1-10 | Published online: 15 Mar 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Taichi Minami, Akiko Kameda & Yasuo Terauchi. (2021) An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opinion on Pharmacotherapy 22:16, pages 2087-2094.
Read now

Articles from other publishers (4)

Saad U Rehman & Faiqa Rahman. (2020) Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus. Cureus.
Crossref
Kyu Hang LeeSang Don LeeNamdu KimKwee Hyun SuhYoung Hoon KimSang Soo Sim. (2019) Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo . The Korean Journal of Physiology & Pharmacology 23:1, pages 55.
Crossref
Atsushi Tanaka & Koichi Node. (2017) Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?. Cardiovascular Diabetology 16:1.
Crossref
Mihoko Matsumura, Yuki Nakatani, Seiichi Tanka, Chie Aoki, Masaaki Sagara, Kazunori Yanagi, Kunihiro Suzuki & Yoshimasa Aso. (2017) Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). Diabetes Therapy 8:4, pages 821-827.
Crossref